Physician Search
 |
 |
 |
DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors
Multiple Cancer Types
This is a Phase 1b / 2, multi-center, open label umbrella study of patients 12 years of age with recurrent or progressive solid tumors with alterations in the key proteins of the RAS / RAF / MEK / ERK pathway, referred to as the MAPK pathway..
Miscellaneous,
Phase I
I/II
Berlin, Jordan
NCT04985604
VICCMD2142
